SLC6A3 and Parkinson disease: In this study, we combined ASL MRI-based assessment of the NVU with [11C]-PE2I PET-based assessment of striatal dopamine transporter density to assess pathophysiologic mechanisms in a prospective clinical cohort of patients with PD.